141
To determine if SUMOylated TopoIIα is the target of PICH in ICRF-193 treated cells, we examined 142 whether TopoIIα depletion (ΔTopoIIα) affects PICH/SUMO2/3 colocalization. To deplete TopoIIα from 143 cells, we created a conditional TopoIIα-knockdown cell line which utilizes the Auxin-Inducible Degron 144 (AID) system (Natsume et al., 2016 , Nishimura et al., 2009 ) (Supplemental Figure S1 and S2). We inserted 145 DNA encoding an AID-Flag tag into the TopoIIα locus (Supplemental Figure S2A Figure S1 ). After auxin addition AID-tagged TopoIIα was degraded to undetectable levels 148 within 6 hours. (Supplemental Figure S2D ). This rapid elimination allows us to examine the effect of 149 TopoIIα depletion in a single cell cycle. In ΔTopoIIα ICRF-193 treated cells, there was an extreme 150 reduction of SUMO2/3 and PICH signals at centromeres (marked by CENP-C) (Figure 2A ). In addition, 151 the incidence of colocalization between PICH/SUMO2/3 at the centromere was also significantly reduced The increased PICH localization to centromeres in ICRF-193 treated cells is likely due to TopoIIα 165 SUMOylation. To determine whether SUMOylation is required for PICH localization to mitotic 166 centromeres, we established cell lines to attenuate the level of SUMOylation at the centromere. To 167 accomplish this, we generated a fusion protein, called Py-S2, which consists of the SENP2-catalytic domain 168 (required for deSUMOylation) (Reverter and Lima, 2004 , and of 169 the N-terminal region of human PIASy (localizes to mitotic centromeres through its specific binding with 170 the RZZ complex at the kinetochore) (Ryu and Azuma, 2010) ). As a negative control, we substituted a 171 cysteine at the position 548 of SENP2 to an alanine (called Py-S2 Mut) to create a loss of function mutant 172 of the SENP2 deSUMOylation activity Lima, 2004, Reverter and Lima, 2006) (Figure 3A ).
173
The activity of the recombinant fusion proteins was verified by Xenopus egg extract (XEE) assay 174 (Supplemental Figure S3 ). As we predicted, addition of the Py-S2 protein to XEE completely eliminates 175 mitotic chromosomal SUMOylation. To our surprise, Py-S2 Mut protein stabilized the SUMOylation of 176 chromosomal proteins, thus acted as a dominant negative mutant. To express the fusion proteins in cells, 177 we created inducible expression cell lines using the Tetracycline inducible system (Supplemental Figure   178 S4). We integrated each of the fusion genes into the AAVS1 safe harbor locus of HCT116 cells using 179 integration plasmids (Natsume et al., 2016) .
180
To test the effect of attenuated SUMOylation during mitosis, cells were synchronized with or without 181 doxycycline treatment, and chromosomes were isolated. Western blotting of mitotic chromosomal fractions 182 showed that expression of Py-S2 attenuated the SUMO2/3 modification on mitotic chromosomes. The 183 attenuation of mitotic SUMO2/3 modification by Py-S2 became apparent in the ICRF-193 treated samples 184 . Consistent with the SUMO2/3 modification profile, Py-S2 185 expression substantially attenuated SUMOylated TopoIIα in ICRF-193 treated cells ( Figure 3B comparing 186 -/+Dox samples with . Notably, the amount of PICH on chromosomes in the ICRF-193 treated 187 sample was reduced when SUMOylation was attenuated by Py-S2 ( Figure 3B comparing -/+Dox samples with . Distinct from the result that displayed complete elimination of SUMO2/3 modification in 189 XEE assays (Supplemental Figure S3A ), the SUMO2/3 and SUMOylated TopoIIα signals were still present 190 in the Py-S2 expressing cells. This is likely due to the mosaic expression of Py-S2 represented by SUMO2/3 191 signals ( Figure 3C ). The SUMO2/3 signals in Py-S2 expressing cells displayed either retention of 192 SUMO2/3 signals on chromosomes suggesting no transgene expression (hereafter referred to as SUMO 193 positive cells), or no SUMO2/3 signal on chromosomes suggesting transgene expression (hereafter referred 194 to as SUMO negative cells) ( Figure 3C ). PICH signals in the SUMO positive cells displayed strong 195 centromeric foci, resembling that of ICRF-193-treated parental HCT116 cells ( Figure 1B ). In SUMO 196 negative cells, the intensity of PICH foci was lessened and a more diffuse non-centromeric signal was 197 observed. Consistent with our observations in XEE assays, TopoIIα signal did not show apparent 198 differences between SUMO positive cells and negative cells, suggesting that inhibition of mitotic 199 SUMOylation does not affect TopoIIα association with chromosomes (Azuma et al., 2005 , Azuma et al., 200 2003 . Colocalization between PICH and TopoIIα foci was reduced in SUMO negative cells (indicated by 201 the magnified image in the merged panel in Figure 3C ). The incidence of PICH/TopoIIα colocalization in Figure 1E ). This strongly suggests that SUMOylation of TopoIIα is required for ICRF-193 induced 207 PICH/TopoIIα colocalization.
208
Consistent with the result obtained from XEE assay (Supplemental Figure S3 ), Western blotting of the 209 mitotic chromosome fraction showed that Py-S2 Mut expression in the HCT116 increased both overall 210 SUMO2/3 modification and TopoIIα SUMOylation ( Figure 4A 
217
Indicating that ICRF-193 treatment with Py-S2 Mut expression did not show a synergistic effect on 218 PICH/TopoIIα colocalization ( Figure 4C -/+ Dox with ICRF-193, red boxes). This suggests that increased 219 chromosomal SUMOylation, presumably TopoIIα SUMOylation, is the major cause of ICRF-193 mediated 220 PICH/TopoIIα colocalization on mitotic chromosomes. Together, these results further strengthen the 221 concept that PICH specifically targets SUMOylated TopoIIα under ICRF-193 treatment.
223
PICH controls the association of SUMOylated TopoIIα with chromosomes at the centromere.
224
Our results suggest that PICH interacts with SUMOylated TopoIIα on mitotic chromosomes in ICRF-225 193 treated cells. To examine the biological function of PICH targeting SUMOylated TopoIIα, we 226 generated a conditional PICH-knockdown cell using the AID system. DNA encoding an AID-Flag tag was 227 introduced at the PICH locus (Supplemental Figure S5A Figure S5D ). To examine the effect of PICH depletion 230 (ΔPICH) on SUMOylated TopoIIα, cells were synchronized in mitosis and chromosomes were isolated.
231
Western blotting analysis of mitotic chromosomes showed that treatment with ICRF-193 increases the 232 amount of PICH ( Figure 5A -Auxin DMSO/ICRF lanes). This is consistent with results from native PICH 233 expressing cells ( Figure 2C , 3B, and 4B), suggesting that tagging PICH with the AID did not alter its 234 response to ICRF-193 treatment. With the addition of auxin, there was no detectable PICH remaining on 6 chromosomes. The function of PICH is amplified by the treatment of cells with presumably 
282
Because the translocase activity of PICH removes proteins from DNA, PICH inhibits decatenation 283 activity of SUMOylated TopoIIα by removing SUMOylated TopoIIα from kDNA. To gain insight into that 284 potential mechanism, we utilized a PICH mutant that has defects in either the SUMO-binding activity 285 or in translocase activity (PICH-K128A) ( Figure 7A ) (Sridharan et al., 2016) . If 286 PICH/SUMO interaction is critical for inhibiting decatenation activity of SUMOylated TopoIIα, the PICH-287 d3SIM mutant would lose its inhibitory function. In addition, we also expect that the PICH translocase 288 activity deficient (PICH-K128A) mutant loses the ability to inhibit the decatenation activity of SUMOylated 289 TopoIIα, because the mutant could not remove SUMOylated TopoIIα from kDNA. Supporting our 290 hypothesis, PICH-d3SIM inhibited SUMOylated TopoIIα decatenation activity substantially less than wild-291 type ( Figure 7B , C), suggesting that the direct SUMO/SIM interactions between PICH and SUMOylated 292 TopoIIα plays a key role in this inhibition. Intriguingly, the translocase deficient PICH mutant further 293 suppressed the SUMOylated TopoIIα decatenation activity (Figure 7B, D) . This suggests that the 294 translocase deficient mutant forms a stable complex with SUMOylated TopoIIα and the catenated kDNA 295 because the translocase mutant retains its DNA binding ability (Kaulich et al., 2012 , Nielsen et al., 2015 296 Sridharan and Azuma, 2016) . Notably, neither mutant showed any significant effect on non-SUMOylated 297 TopoIIα ( Figure 7B ) similar to wild-type PICH. This suggests that PICH binding to DNA does not inhibit 298 the decatenation activity of TopoIIα, but rather it forms a complex with SUMOylated TopoIIα and prevents 299 its decatenation activity. Taken together, our results suggest that PICH recognizes the SUMO moieties on 300 TopoIIα through its SIMs and removes SUMOylated TopoIIα from DNAs using its translocase activity.
301
In conclusion, our results show that PICH targets SUMOylated TopoIIα to attenuate its interaction with 
308

Discussion
309
The identification of PICH led to the discovery of UFBs which represent the existence of tangled DNA 310 during mitosis (Biebricher et al., 2013 , Wang et al., 2008 . The importance of TopoIIα in resolving UFBs 311 is highlighted by a study showing an increased incidence of PICH-positive UFBs in TopoIIα-knockdown 312 cells (Spence et al., 2007) . Likewise, knocking out PICH sensitizes cells to ICRF-193 treatment, suggesting 313 that PICH plays a role in resolving stalled TopoIIα mediated UFB formation (Kurasawa and Yu-Lee, 2010, 314 Nielsen et al., 2015) . The current model indicates that the requirement of PICH in ICRF-193 treated cells 315 is due to the necessity of PICH to increase TopoIIα decatenation activity. (Nielsen et al., 2015) . However, 316 ICRF-193 causes TopoII to stall at the last stage of the SPR when two DNA strands are held within TopoII. closed clamp conformation with two DNA strands are bound within it, and this structure is particularly 326 susceptible to SUMOylation. PICH then binds SUMOylated TopoIIα utilizing its SIMs and removes it from 327 its stalled position using its translocase activity, resulting in the release of two resolved DNA strands held 328 by stalled TopoIIα (Figure 8 ). The process of removing stalled SUMOylated TopoIIα from decatenated, 329 but not released DNA, resolves chromosome bridges which were originally shown to be upregulated in the 330 PICH knockout/knockdown experiments (Kurasawa and Yu-Lee, 2010, Nielsen et al., 2015) .
331
One remaining question is how SUMOylated TopoIIα becomes a critical target of PICH among all of 332 the SUMOylated chromosomal proteins in the ICRF-193 treated cells. Our in vitro assays and previous 333 reports showed that PICH interacts with TopoIIα and affects TopoIIα activity (Nielsen et al., 2015) . This 334 suggests that PICH has a binding affinity for TopoIIα regardless of its modification status, thus due to this 335 intrinsic binding affinity PICH preferentially binds SUMOylated TopoIIα over other SUMOylated proteins.
336
Another possibility is the contribution of other posttranslational modifications on TopoIIα that are 337 influenced by ICRF-193 treatment. TopoIIα is known to be phosphorylated at its C-terminal domain with 338 ICRF-193 treatment in mammalian cells and fission yeast (Luo et al., 2009 , Nakazawa et al., 2019 . The 339 phosphorylation is suggested to play a critical role in a TopoII-dependent cell cycle checkpoint. We 340 demonstrated that SUMOylation of TopoIIα promotes binding with Claspin which is an upstream regulator of Chk1 (Kumagai and Dunphy, 2003) , and Haspin (Yoshida et al., 2016) the kinase 342 responsible for phosphorylating H3T3 (Dai et al., 2005) . In the future, it is essential to study whether kinases 343 bound to SUMOylated TopoIIα affect the phosphorylation of TopoIIα and the activity of PICH for 344 removing SUMOylated TopoIIα from chromosomes.
345
Although SUMOylated TopoIIα is a critical target of PICH in the ICRF-193 treated cells, PICH also 346 interacts with other SUMOylated proteins and may control their binding to chromosomes. This is supported 347 by our results which show retention of other SUMO2/3 modified proteins on mitotic chromosomes in 348 ΔPICH cells (Supplemental Figure 6B +Auxin lane). We previously showed that PICH interacts with 349 SUMOylated PARP1 as well as a tetrameric SUMO chain, suggesting that PICH promiscuously binds 350 SUMOylated proteins . Both loss of translocase activity and SUMO-binding activity 351 of PICH leads to chromosome bridge formation (Sridharan and Azuma, 2016) which could derive from the 352 increased incidence of UFBs due to stalled SUMOylated TopoIIα. However, other SUMO2/3 modified 353 chromosomal proteins remodeled by PICH might contribute to chromosome bridge formation in loss of 354 PICH cells (Baumann et al., 2007 , Kurasawa and Yu-Lee, 2010 , Nielsen et al., 2015 . Supporting this idea, 355 it has been shown that defects in the regulation of mitotic SUMOylation causes similar chromosome bridge 356 formation. For example, loss of a SUMO E3 ligase showed mitotic defects and chromosome bridge 357 formation in Drosophila (Hari et al., 2001) . Also, defects in deSUMOylation enzymes induce defective 358 mitosis with chromosome bridge formation in cultured cells (Cubenas-Potts et al., 2013 , Mukhopadhyay et 359 al., 2010 , Zhang et al., 2008 . Several potential key SUMOylated chromosomal proteins were proposed to 360 explain this SUMOylation-dependent defect (Myatt et al., 2014 , Schimmel et al., 2014 , Zhang et al., 2008 .
361
Once we identify which SUMOylated chromosomal proteins are controlled by PICH, and characterize their 362 abundance on chromosomes, we will be able to elucidate the role of PICH as a "SUMOylated chromosomal (Cong et al., 2013) . Guide plasmid for targeting AAVS1 locus 397 (AAVS1 T2 CRIPR in pX330) was obtained from Addgene (#72833) (Natsume et al., 2016) . Mutations 398 were introduced in PAM sequences on the homology arms. The X. laevis TopoIIα cDNA and human PICH 399 cDNA were subcloned into a pPIC 3.5K vector in which calmodulin-binding protein CBP-T7 tag sequences 400 were inserted as previously described (Ryu et al., 2010b, Sridharan and . All mutations in 401 the plasmids were generated by site-directed mutagenesis using a QuikChangeII kit (Agilent) according to 402 manufacturer's instructions. All constructs were verified by DNA sequencing.
404
Recombinant protein expression and purification, and preparation of antibodies
405
Recombinant TopoIIα and PICH proteins were prepared as previously described (Ryu et al., 2010b, 406 Sridharan and Azuma, 2016) . In brief, the pPIC 3. dnUbc9, and SUMO paralogues were expressed in Rosetta2(DE3) and purified as described previously 423 (Ryu et al., 2010a) .
424
To generate the antibody for human PICH, the 3'end (coding for amino acids 947~1250) was amplified Figure S2D and S4C ).
502
Xenopus egg extract assay for mitotic chromosomal SUMOylation analysis 503 Low speed cytostatic factor (CSF) arrested Xenopus egg extracts (XEEs) and demembraned sperm nuclei 504 were prepared following standard protocols (Murray, 1991 , Powers et al., 2001 . To prepare the mitotic 505 replicated chromosome, CSF extracts were driven into interphase by adding 0.6mM CaCl2. Demembraned 506 sperm nuclei were added to interphase extract at 4000 sperm nuclei/μl, then incubated for ~60 min to 507 complete DNA replication confirmed by the morphology of nuclei. Then, equal volume of CSF XEE was 508 added to the reactions to induce mitosis. To confirm the activities of Py-S2 proteins on mitotic 509 SUMOylation, the Py-S2 proteins or dnUbC9 were added to XEEs at a final concentration of 30nM and 510 5M, respectively, at the onset of mitosis-induction. After mitotic chromosome formation was confirmed 511 by microscopic analysis of condensed mitotic chromosomes, chromosomes were isolated by centrifugation 512 using 40% glycerol cushion as previously described (Yoshida et al., 2016) then the isolated mitotic 513 chromosomes were boiled in SDS-PAGE sample buffer. Samples were resolved on 8-16% gradient gels 514 and subjected to Western blotting with indicated antibodies. Signals were acquired using LI-COR Odyssey
515
Fc digital imager and the quantification was performed using Image Studio Lite software.
516
The following primary antibodies were used for Western blotting: Rabbit anti-Xenopus TopoIIα (1:10,000),
517
Rabbit anti-Xenopus PARP1 (1:10,000), Rabbit anti-SUMO2/3 (1:1,000) (all prepared as described 518 previously (Ryu et al., 2010a) ), anti-Histone H3 (#14269, Cell Signaling). 
520
Preparation of mitotic cells and chromosome isolation
538
The following primary antibodies were used for Western blotting: Rabbit anti-PICH (1:1,000) , Rabbit anti-539 TopoIIα (1:20,000) (both are prepared as described above), Rabbit anti-SUMO2/3 (1:1,000), Rabbit anti-540 Histone H2A (1:2,000) (#18255, Abcam), Rabbit anti-Histone H3 (1:2,000) (#14269, Cell Signaling),
541
Rabbit anti-PIASy (1:500) (as described in (Azuma et al., 2005) ), Mouse anti-β-actin (1:2,000) (#A2228,
542
Sigma-Aldrich), Mouse anti-myc (1:1,000) (#9E10, Santa Cruz), Mouse anti-β-tubulin (1:2,000) (#, Sigma-543 Aldrich), Mouse anti-Flag (1:1,000) (#F1804, Sigma-Aldrich).
545
Cell fixation and staining
546
To fix the mitotic cells on fibronectin coated cover slips, cells were incubated with 4% paraformaldehyde 547 for 10 minutes at room temperature, and subsequently washed three times with 1X PBS containing 10mM 548 Tris-HCl to quench PFA. Following the fixation, the cells were permeabilized using 100% ice cold 549 Methanol in -20°C freezer for 5 minutes. Cells were then blocked using 2.5% hydrolyzed gelatin for 30 550 minutes at room temperature. Following blocking the cells were stained with primary antibodies for 1 hour 551 at room temperature, washed 3 times with 1X PBS containing 0.1% tween20, and incubated with secondary 552 for 1 hour at room temperature. Following secondary incubation cells were washed 3 times with 1x PBS-T 553 and mounted onto slide glass using VECTASHIELD® Antifade Mounting Medium with DAPI (#H-1200,
554
Vector laboratory) and sealed with nail polish. Images were acquired using the Plan Apo 100x/1.4 objective 555 lens on a Nikon Ti Eclipse microscope equipped Exi Aqua CCD camera (Q imaging) or a Nikon TE2000-556 U equipped PRIME-BSI CMOS camera (Photometrics) with MetaMorph imaging software. Adobe 557 Photoshop (CS6) software was used to process the images for signal intensities and size according to journal 558 policy. The Fiji colocalization threshold software was used to measure colocalization coefficients for at 559 least 20 cells in three independent experiments.
560
The following primary antibodies were used for staining: Rabbit anti-PICH 1:800, Rabbit anti-human 561 TopoIIα 1:1000 (both are prepared as described above), Mouse anti-human TopoIIα 1:300 (#Ab 189342,
562
Abcam), Mouse anti-SUMO2/3 (#12F3, Cytoskeleton Inc), and Guinea Pig anti-SUMO2/3 (1:300) ( 563 prepared as previously described (Ryu et al., 2010a) ).
565
Statistical analysis 566 All statistical analyses were performed with either 1-or 2-way ANOVA, followed by the appropriate post-567 hoc analyses for each of the analysis using GraphPad Prism 8 software.
569
Animal use 
588
NP conducted experiments for initial validation of the genome edited cell lines expressing Py-S2. BL 589 performed analysis in Figure 6 . VA, AA, and MD established AID-mediated degradation system by 590 optimizing Os-TIR1 integration locus and creating constructs for genome editing by CRISPR/Cas9 for that 591 system. YA designed the study, supervised project, and wrote the manuscript.
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The authors declare no competing financial interests. Representative Western blotting of clones is shown. An anti-Flag antibody was used to detect AID-Flag tagged TopoIIα (~190kDa) in the 700 channel (red) and anti-TopoIIα antibodies were used to detect both AID-Flag tagged TopoIIα and untagged TopoIIα (~160kDa) in the 800 channel (green). Anti-β-tubulin was used as a loading control. (C) Genomic DNA from hygromycin resistant clones was extracted for PCR analysis using indicated primers shown in A. Representative result of PCR amplification was shown. Clones showing only 3kbp DNA fragment are homozygous AID integrated clones (#72, #79 and #80).
(D)
The clone #79 was treated with auxin for 2, 4, and 6-hours, and evaluated the TopoIIα depletion by Western blotting. As a control, DLD-1 OsTIR1#50 parental cells were treated with auxin for 6 hours (DLD1 TIR1). Whole cell lysates were subjected to Western blotting analysis using indicated antibodies. Clone #79 was chosen for further analysis in the subsequent experiments showed in Figure 2 . Figure S3 . Testing SUMO modulating proteins in the Xenopus laevis egg extract system. (A) Recombinant Py-S2 or Py-S2 Mut proteins were added to Xenopus laevis egg extract upon induction of mitosis, and the chromosomes were isolated. Chromosome samples were subjected to Western blotting with anti-SUMO2/3 antibody. (B) Chromosome samples in A were subjected to Western blotting with anti-Xenopus TopoIIα antibody to detect both TopoIIα (~160kDa) and SUMOylated TopoIIα (marked with red asterisks), and anti-Xenopus PARP1 antibody to detect both PARP1 (~100kDa) and SUMOylated PARP1 (marked with red asterisks). Anti-histone H3 antibody was used as a loading control. 30nM of Py-S2 protein was sufficient to eliminate chromosomal SUMOylation, which is the equivalent concentration of endogenous PIASy protein in XEE, suggesting that the Py-S2 effectively deSUMOylates chromosomal SUMOylated proteins at a physiologically relevant concentration. Note that the concentration of dnUbc9 required for complete inhibition of chromosomal SUMOylation is 5M in XEE, which is not within the physiological range and is difficult to induce a high expression level of dnUbc9 in cells. Addition of the Py-S2 C548A mutant (Py-S2 Mut) increased SUMO2/3 modification in chromosomal samples, including both TopoIIα SUMOylation and PARP1 SUMOylation. This suggests that the Py-S2 Mut acts as a dominant mutant for stabilizing SUMOylation.
Supplemental Figure S4. Construction of Py-S2 and Py-S2 Mut HCT116 cell lines. (A)
Experimental scheme to introduce inducible Py-S2 and Py-S2 Mut into AAVS1 locus of HCT116 cells. Cells were transfected with a modified form of pMK243 (obtained from Addgene) AAVS1-TetON3G-Py-S2 (or Py-S2 Mut)-Puro-AAVS1 and AAVS1 T2 CRISPR/Cas9 to target AAVS1 locus. For the screening of the transgene integrated clones, primers were designed to amplify the 5' region (2.56kb) and 3' region (3.26kb) of the integration site respectively. (B) After the selection using 1ug/mL Puromycin, 2 clones each per construct were further subjected to genomic PCR to confirm the integration of the transgene. (C) The whole cell lysates obtained from the candidate clones were subjected to Western Blotting to confirm the inducible expression of Py-S2 and Py-S2 Mut proteins. Anti-PIASy antibodies were used to detect expression of fusion proteins (+Dox) or not (-Dox), anti-H3 antibodies were used as a loading control. Figure S6 . Elimination of AID-tagged PICH foci on mitotic chromosomes by addition of auxin, and effect of PICH depletion on chromosomal SUMO2/3 modified proteins. (A) DLD-1 cells with endogenous PICH tagged with an auxin inducible degron (AID) were synchronized in mitosis and treated with DMSO or ICRF-193. Auxin was added 6 hours after Thymidine release. Mitotic cells obtained by shake-off were plated onto fibronectin coated coverslips and subsequently stained with indicated antibodies. DNA was labeled with DAPI. PICH foci on mitotic chromosomes were completely eliminated with auxin in both DMSO and ICRF-193 treated cells. (B) Isolated mitotic chromosomes were subjected to Western blotting with indicated antibodies. Signals of SUMO2/3 modified chromosomal proteins are increased in +Auxin (ΔPICH) sample. 
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